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Serum concentrations of the biomarkers
CA125, CA15-3, PSA and PAPP-A in
early pregnancy
Melissa Stemp1,2, Peter Roberts2, Allison McClements1,
Vincent Chapple1 and Phillip Matson1,2
Abstract
Blood samples were collected serially from 14 women with healthy pregnancies, beginning in gestational week 4 at the time of a
positive pregnancy test through to the identification of a foetal heart by ultrasound. Six biomarkers were measured in the serum
retrospectively including two reproductive hormones (progesterone and human chorionic gonadotrophin (hCG)) and four
additional biomarkers (prostate-specific antigen (PSA), cancer antigen 15-3 (CA15-3), cancer antigen 125 (CA125) and
pregnancy-associated plasma protein A (PAPP-A)) measured on a Siemens Centaur XP and a Roche Cobas e411 automated
analysers, respectively. The progesterone and hCG results were unremarkable following established patterns, but distinctive
patterns of change were seen in the other four biomarkers during this period of early pregnancy. PAPP-A and PSA levels rose
steadily as the pregnancies progressed, while CA125 levels rose until week 5.5 and then returned to baseline values. CA15-3
serum concentrations were observed to drop as the pregnancies progressed. These biomarker results suggest further inves-
tigation is warranted to allow a non-invasive correlation of the biomarkers with the various stages of embryogenesis,
implantation and placentation.
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Introduction
The first few weeks of human pregnancy are characterized by
rapid and synchronized developments in embryogenesis,
implantation and placentation (Norwitz et al., 2001). Unfortu-
nately, non-invasive imaging techniques between 2 and 5
weeks after ovulation are often limited technically to measure-
ments of embryonic size and gestational sac volume (Rousian
et al., 2010, 2011) aimed at predicting foetal outcome (Oh et al.,
2002). A number of biomarkers are used to monitor physiolo-
gical processes in reproductive medicine (Palmer and Barnhart,
2013), and these can be used to reveal pathophysiology when
used either alone or in combination with other biomarkers.
While most biomarkers have a principal association with a
particular disease, some are not always specific for that disease
but can be found in unexpected situations or used in the
detection and monitoring of apparently unrelated conditions.
Serum biomarkers in early pregnancy may prove useful in
revealing some of the changes that occur following implanta-
tion during embryogenesis and placentation, and the availabil-
ity of validated reagents for the measurement of a number of
novel tumour markers (Wu et al., 2007) and establishedmarkers
of pregnancy (Pillai et al., 2016) may well provide this
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opportunity of monitoring non-invasively the different events
in early pregnancy. The present study therefore measured, in
addition to the recognized reproductive hormones human chor-
ionic gonadotrophin (hCG) and progesterone, four biomarkers
(pregnancy-associated plasma protein A (PAPP-A), prostate-
specific antigen (PSA), cancer antigen 15-3 (CA15-3) and can-
cer antigen 125 (CA125)) that have been linked directly or
indirectly with female reproduction. PAPP-A is useful in a
combined test with free b-hCG and foetal nuchal translucency
for the identification of increased risk of Down’s syndrome
(Avgidou et al., 2005) and miscarriage (Rissanen et al.,
2006), although it is not regarded as being adequate as a screen
on its own for pregnancy viability (Brameld et al., 2008). PSA is
a usual choice as it is more familiar as a marker for prostate
cancer in men (Armbruster, 1993; Schro¨der et al., 2012) but a
peptidase that has curiously been associated with breast tissue
and shows temporal changes during the ovarian cycle in women
(Diamandis and Yu, 1995). CA125 is principally used as a
marker for ovarian cancer (Bast et al., 1981) but it has found
a role in the non-invasive detection and monitoring of endome-
triosis (Pittaway and Fayez, 1986). CA15-3 is mainly used in
the monitoring of women with breast cancer (Clinton et al.,
2003; Duffy et al., 1999; O’Brien et al., 1994). It is a mucin-
like glycoprotein encoded by the MUC1 gene and has a clear
association with reproduction as MUC1 is heterogeneously
expressed on the surface of epithelial cells, including those in
the breast and upper reproductive tract, and is thought to pre-
vent embryo implantation (Al-Azemi et al., 2009).
The present study therefore measured six serum biomarkers
of pregnancy, two reproductive hormones (progesterone and
hCG) and four additional biomarkers linked with female
reproduction (PSA, CA15-3, CA125 and PAPP-A) in healthy
women during the early stage of a viable pregnancy from the
time of a positive pregnancy test to 7 weeks’ gestation. Results
were analysed relative to the last menstrual period in an
attempt to identify any longitudinal changes that may provide
insight into the physiological processes occurring at this time
of the pregnancy.
Materials and methods
Ethical approval, including approval of patient information
sheets and consent forms, was approved by both the Joondalup
Health Campus Research Ethics Committee and the Edith
Cowan University Human Research Ethics Committee. All
blood samples were taken as part of the routine management
of the women at Fertility North, but consent was sought for the
analysis of additional compounds not indicated medically. The
data from this study formed part of a thesis submitted to Edith
Cowan University towards a master of science degree which
has now been awarded.
Patients
Consecutive women with a positive pregnancy test between 1
February 2012 and 31 July 2012, and with no evidence of
cancer (clinical history and examination) or endometriosis (pre-
vious laparoscopy in the last 12 months), were approached
during their routine clinical management to participate. The
14 pregnant women meeting the above entry criteria and agree-
ing to give consent for the additional tests had all conceived
following fertility treatment, were routinely given progesterone
supplements from the mid-luteal phase and were monitored
until a foetal heart was seen on ultrasound. All pregnancies
progressed uneventfully and resulted in the birth of a healthy
singleton baby.
Sample processing and analysis
Blood was collected using syringes and transferred into 5-ml
Vacutainer SST™ tubes (Becton Dickinson, UK) before deliv-
ery to the laboratory. The blood was allowed to clot at room
temperature and then centrifuged at 1300  g for 4 min, with
the tubes then being ready for loading directly onto the auto-
mated analyser upon removal of the lids. Serum progesterone
and hCG were measured on a Siemens Centaur CP automated
analyser (Siemens, Bayswater, Victoria, Australia) within 1 h of
the blood being collected, and all between-run coefficients of
variation were <5%. The serum was then stored in secondary
tubes at 80C before being analysed in one batch on a Roche
Cobas e411 automated analyser (Roche Diagnostics, Germany)
for the biomarkers PAPP-A, CA125, CA15-3 and total PSA.
Assay variability for the biomarkers was determined by analys-
ing pooled patient serum in the analytical range for this study,
and the within-run variability for the biomarkers (CA125 <3%;
CA15-3 <2%; PAPP-A <13%; PSA <3%) was invariably less
than the between-run variability (CA125 <5%; CA15-3 <7%;
PAPP-A <15%; PSA <39%). Assay sensitivity for CA125,
CA15-3, PAPP-A and PSA was 0.6 U/ml, 1.00 U/ml, 4.00
mIU/L and 0.003 ng/ml, respectively.
Statistical analysis
The response variable (PSA, CA125, CA15-3 and PAPP-A)
was log transformed before analysis. Gestation was included
as a fixed effect factor and ‘Subject’ and ‘Time’ were mod-
elled as random effects. The interaction between Group and
Gestation was also modelled. The analyses were done using
the R version 3.0.0 computing software (Team, 2013), models
built using the ‘nlme’ mixed models package (Pinheiro et al.,
2012) and graphics produced using the ‘ggplot2’ package
(Wickham, 2009).
Results
Reproductive hormones
Results for progesterone and hCG levels, measured routinely in
pregnancy, are shown in Table 1. They followed standard pat-
terns of change, confirming that the modelling and expression
of results according to the stage of pregnancy was appropriate.
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PAPP-A, CA125, PSA and CA15-3 during early pregnancy
The biomarker concentrations are shown in Table 2. Concen-
trations of PAPP-A increased steadily from 6.51+ 0.56 mIU/L
at 4 weeks to 125.38 + 22.11 mIU/L at 7 weeks, and the
changes seen were highly significant (p  0.0001) in these
healthy viable pregnancies. During early pregnancy, there was
a significant effect of the stage of gestation (p ¼ 0.0012) on
CA125 concentration. At week 4 of gestation, the average
CA125 concentration was 22.79+ 3.73 U/ml with peak levels
occurring at around 5.5 weeks (57.98 + 27.45 U/mL) before
reducing again to 29.92 + 6.44 by week 7. However, this
overall pattern of change did not fully reflect the changes seen
in individual women whose peak CA125 concentration
occurred anywhere between 2.5 and 5 weeks after ovulation
(Figure 1). Normalizing the data relative to the peak concentra-
tion (Figure 2) revealed a more consistent pattern. Only 64% (9/
14) of the pregnant women had detectable levels of PSA at
some point during pregnancy, but in those women the concen-
tration of PSA increased steadily from 0.005 + 0.001 at 4
weeks to 0.01 + 0.003 at 7 weeks, with an average increase
of 0.0015+ 0.0004 ng/ml for every week increase in gestation
time (p ¼ 0.000). In effect, the concentration of PSA in the
serum of these women doubled from week 4 to 7 of gestation.
All pregnant women had detectable levels of CA15-3 and there
was a significant effect of the stage of gestation on the CA15-3
concentration (p¼ 0.000). The average concentration of CA15-
3 was 16.44+ 2.22 U/ml at 4 weeks gestation and over the 3
weeks reduced to an average of 12.97+ 2.35 U/ml (Table 2).
Discussion
The use of serum markers requires consideration of both the
technical capability of the assays, and the biological relevance
of the marker under investigation. While biomarker immunoas-
says allow precise qualitative measurements to be made when
measuring analytes, different assays can result in different
numerical values due to differences in choice of reagent or their
calibration. This is important when comparing work from dif-
ferent laboratories or over different time frames. For example,
the expression of PAPP-A results in milli-international units per
millilitre in the present study compared to microgram per litre
elsewhere (Sinosich et al., 1982) and reflects the change in
methodology and the move to a different standardization.
CA125 has varied forms which presents a challenge to assay
accuracy, and large differences in results can be seen between
the Siemens and Panomics methods (McLemore et al., 2012).
Between-method differences can occur with CA15-3 due to
differences in calibration rather than specificity (Klee and
Schreiber, 2004).
The pattern seen for progesterone and hCG reflects the
pattern seen serially in individual women, and this gives con-
fidence that the sampling strategy and data analysis did not
have an adverse effect upon the findings. The relatively con-
stant progesterone during early pregnancy was possibly due to
the continued administration of exogenous progesterone as a
luteal support until a foetal heart was observed. Changes dur-
ing the ovarian cycles of these patients for the reproductive
hormones and other biomarkers have been published previ-
ously, with CA125 and CA15-3 both being influenced by the
stage of the ovarian cycle (Stemp et al., 2014, 2015). In the
present study, different patterns of change were seen between
the four biomarkers during early pregnancy, and presumably
reflect different processes involved in implantation, embryo-
genesis and placentation. PAPP-A and PSA rose steadily as
the pregnancy progressed, while CA125 rose until week 5.5
before returning to baseline values, while CA15-3 levels
decreased during pregnancy.
PAPP-A has been described in normal pregnancy (Bersinger
et al., 1986; Westergaard et al., 1983), and the findings in the
present study that PAPP-A rises steadily as the healthy preg-
nancy progressed mirrors these earlier studies. However, it has
been shown previously that healthy pregnancies following
assisted reproduction have reduced PAPP-A levels in the first
trimester compared to naturally conceived pregnancies (Amor
et al., 2009). This biomarker is therefore giving information not
apparent by other means and may be revealing some impair-
ment of early implantation with some forms of assisted repro-
duction. Unfortunately, the lower levels found can also increase
the risk of receiving a “false-positive” result at the routine first
trimester screen and having an unnecessary chorionic villus
biopsy or amniocentesis (Amor et al., 2009).
CA125, a high molecular mass mucin-type molecule, is a
tumour biomarker that is used extensively to monitor epithelial
ovarian cancer (Bast et al., 1981), but it also is found elsewhere
such as during the ovarian cycle (Nonogaki et al., 1991), in
association with endometriosis (Pittaway and Fayez, 1986), in
pregnancies that are destined to miscarry (Azogui et al., 1996),
and with pelvic inflammatory disease (Mozas et al., 1994).
Consequently, concern has been expressed that this tumour
marker can cross the clinical cut-offs for cancerous disease
during normal reproductive function (Touitou et al., 1989).
Indeed, 5/14 women in the current study had CA125 values that
exceeded the recommended clinical cut-off of 35 U/ml. The rise
and fall in serum CA 125 seen in the present study is consistent
with the changes seen during the first trimester previously
(Jacobs et al., 1990).
Table 1. Reproductive hormone concentrations (mean+ SEM) in
early pregnancy.a
Gestational age (weeks)
Progesterone
(nmol/L) hCG (IU/L)
4 179.2+ 42.1 296.8+ 70.9
4.5 179.7+ 43.5 177.3+ 262.0
5 179.3+ 37.2 5359.6+ 1212.8
5.5 196.8+ 43.4 15,085.9+ 2666.5
6 169.3+ 34.9 31,725.0+ 5367.8
6.5 167.9+ 42.5 48,306.8+ 7371.0
7 287.8+ 78.8 52,191.3+ 11,310.7
SEM: standard error of the mean; hCG: human chorionic gonadotrophin.
aTime was relative to the last menstrual period.
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PSA was thought to be produced exclusively by prostatic
tissue and was therefore used to monitor prostate cancer
(Armbruster, 1993). However, it is a serine protease also known
as kallikrein-3 (Lawrence et al., 2010) and has been associated
with a number of tissues and biological events in women (Dia-
mandis and Yu, 1995) such as in the breast (Yu et al., 1996) and
during the ovarian cycle (Aksoy, et al., 2002; Zarghami et al.,
1997). PSA has also been found in placental tissue during preg-
nancy and is secreted in vitro by placental cells in culture
(Malatesta et al., 2000) thereby being a potentially useful bio-
marker of pregnancy. The steady rise seen in the present study
as the pregnancy progressed is consistent with the increase in
serum oestradiol concentrations seen in pregnancies at Fertility
North (K Hamilton, personal communication) and a previous
report that PSA production and secretion by placental tissue in
culture is upregulated by 17b-oestradiol (Malatesta et al.,
2000). The main limitation, however, was the lack of sensitivity
of the assay used in the current study presumably because it has
been optimized for use in the screening of men for prostate
disease. This meant that the PSA could not be detected in
36% of the women tested, but subsequent work using a more
sensitive assay would seem warranted.
CA15-3, a tumour biomarker, is a mucin-like glycoprotein
encoded by the MUC1 gene whose main clinical use of the
assay is in the monitoring of women with breast cancer (Duffy
et al., 1999). Nevertheless, it has a clear association with repro-
duction since MUC1 is heterogeneously expressed on the sur-
face of epithelial cells, including those in the breast and upper
reproductive tract and is thought to prevent embryo implanta-
tion (Al-Azemi et al., 2009). It has been suggested that the
human blastocyst can produce certain factors that remove
MUC1 from a site to facilitate implantation in the endometrium
(Meseguer et al., 2001), and this is consistent with the findings
of the present study where the CA15-3 levels decreased as the
pregnancies progressed.
Conclusion
A series of six biomarkers have been described that show dif-
ferent patterns of change during early pregnancy. PAPP-A and
PSA rose steadily as the pregnancies progressed, CA125 rose
until week 5.5 and then returned back to baseline values, while
CA15-3 serum concentrations decreased during pregnancy; the
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Figure 1. The frequency distribution of the time of the peak CA125
concentration identified in 14 pregnant women. The time was the
gestational age relative to the last menstrual period. CA125: cancer
antigen 125.
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Figure 2. The CA125 concentrations (mean+ SEM) determined in
the serum of 14 pregnant women. Time was relative to the maximum
value for each woman. CA125: cancer antigen 125; SEM: standard
error of the mean.
Table 2. The biomarker concentrations (mean+ SEM) determined in the serum of 14 pregnant women.a
Gestational age (weeks)
Biomarker concentration
PAPP-A (mIU/L) CA125 (U/ml) PSA (ng/ml) CA15-3 (U/ml)
4 6.51+ 0.56 22.79+ 3.73 0.005+ 0.001 16.44+ 2.22
4.5 6.86+ 0.40 30.40+ 6.02 0.005+ 0.001 15.19+ 1.56
5 8.29+ 0.66 47.65+ 15.12 0.006+ 0.001 14.59+ 1.60
5.5 14.58+ 1.47 57.98+ 27.45 0.007+ 0.001 14.30+ 1.58
6 34.41+ 4.45 48.15+ 19.13 0.008+ 0.001 14.28+ 1.54
6.5 59.37+ 7.09 42.59+ 10.56 0.009+ 0.001 14.04+ 1.53
7 125.38+ 22.11 29.92+ 6.44 0.010+ 0.003 12.97+ 2.35
SEM: standard error of the mean; PAPP-A: pregnancy-associated plasma protein A; CA125: cancer antigen 125; PSA: prostate-specific antigen; CA15-3: cancer
antigen 15-3.
aTime was relative to the last menstrual period.
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two reproductive hormones, progesterone and hCG, followed
expected patterns. These biomarker results suggest further
investigation is warranted to permit a non-invasive correlation
of the biomarker levels with the various stages of embryogen-
esis, implantation and placentation.
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